Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Adjuvant treatment with empagliflozin or semaglutide increases endothelial progenitor cells in subjects with well-controlled type 1 diabetes mellitus
Avtorji:ID Navodnik-Preložnik, Maja (Avtor)
ID Reberšek, Katarina (Avtor)
ID Klinar, Katarina (Avtor)
ID Janež, Andrej (Avtor)
ID Podgornik, Helena (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (1,64 MB)
MD5: 5182BCBA833225E7C59ECFBDCA9B5F53
 
URL URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/1467-3045/47/1/54
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Circulating endothelial cells (CECs) and endothelial progenitor cells (EPCs) are promising markers of vascular damage and endothelial regeneration potential. We focused on the detection of CECs and EPCs using flow cytometry with regard to analytical challenges and its suitability for routine testing. As part of a clinical validation, CECs and EPCs were measured in blood samples from 83 subjects with type 1 diabetes (T1DM), evaluating an adjuvant intervention with two different antidiabetic drugs, empagliflozin (N = 28) and semaglutide (N = 29). Both groups receiving adjuvant therapy were compared with the insulin-only group (N = 26) at two time points: before the start of therapy and after 12 weeks of adjuvant therapy. All three groups were comparable regarding demographic characteristics and concomitant risk factors. Absolute and relative endothelial cell count at baseline were low and comparable to those of healthy individuals. In the group receiving empagliflozin or semaglutide, a significant increase in EPC was observed after 12 weeks of treatment. We demonstrated that EPCs have the potential to serve as markers for monitoring the efficacy of adjuvant therapy in T1DM patients. However, before their implementation in clinical practice, the flow cytometry protocol for CEC and EPC identification and quantification must be standardized.
Ključne besede:flow cytometry, type 1 diabetes mellitus, endothelial progenitor cells
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:str. 1-12
Številčenje:Vol. 47, iss. 1, (article no. 54)
PID:20.500.12556/DiRROS-24459 Novo okno
UDK:616.4
ISSN pri članku:1467-3045
DOI:10.3390/cimb47010054 Novo okno
COBISS.SI-ID:222632963 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis z dne 16. 1. 2025;
Datum objave v DiRROS:28.11.2025
Število ogledov:175
Število prenosov:64
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Current issues in molecular biology
Skrajšan naslov:Curr. issues mol. biol.
Založnik:Caister Academic.
ISSN:1467-3045
COBISS.SI-ID:521769497 Novo okno

Gradivo je financirano iz projekta

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0289-2019
Naslov:Značilnosti malignih neoplazem, pomembne za diagnozo ter napoved poteka bolezni in izida zdravljenja

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Univerzitetni klinični center Ljubljana
Številka projekta:20220028
Naslov:Določanje endotelijskih predniških in cirkulirajočih celic s pretočno citomtrijo

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:pretočna citometrija, sladkorna bolezen tip 1, endotelne matične celice


Nazaj